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Abstract
Background: Central retinal vein occlusion (CRVO) is a common retinal vascular disorder with
potentially complications: (1) persistent macular edema and (2) neovascular glaucoma. No safe
treatment exists that promotes the return of lost vision. Eyes with CRVO may be predisposed to
vitreous degeneration. It has been suggested that if the vitreous remains attached to the macula
owing to a firm vitreomacular adhesion, the resultant vitreous traction can cause inflammation with
retinal capillary dilation, leakage and subsequent edema6. The roll of vitrectomy in ischemic CRVO
surgical procedures has not been evaluated.
Case presentation: This is a non comparative, prospective, longitudinal, experimental and
descriptive series of cases. Ten eyes with ischemic CRVO. Vitrectomy with complete posterior
hyaloid removal was performed. VA, rubeosis, intraocular pressure (IOP), and macular edema were
evaluated clinically. Multifocal ERG (m-ERG), fluorescein angiography (FAG) and optic coherence
tomography (OCT) were performed. Follow-up was at least 6 months. Moderate improvement of
visual acuity was observed in 60% eyes and stabilized in 40%. IOP changed from 15.7 ± 3.05 mmHg
to 14.9 ± 2.69 mmHg post-operative and macular edema from 976 ± 196 µm to 640 ± 191 µm to
six month. The P1 wave amplitude changed from 25.46 ± 12.4 mV to 20.54 ± 11.2 mV.
Conclusion: A solo PPV with posterior hyaloid removal may help to improve anatomic and
functional retina conditions in some cases. These results should be considered when analyzing
other surgical maneuvers.
Background
Central retinal vein occlusion (CRVO) is a common reti-
nal vascular disorder with potentially complications like
reduced vision resulting from extensive intraretinal
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hemorrhage, retinal ischemia and persistent macular
edema and neovascular glaucoma secondary to iris neo-
vascularization. Severe visual loss may develop, including
blindness. Capillary nonperfusion and retinal ischemia
develop in 34% of patients with CRVO. Iris neovasculari-
zation and neovascular glaucoma may occur in 45–85%
of ischemic CRVO [15,20,23,24]. No safe treatment exists
that promotes the return of lost vision. Treatments that
target the secondary effects of venous occlusion, such as
grid laser photocoagulation for macular edema and pro-
phylactic panretinal laser photocoagulation for nonper-
fused CRVO, were shown to be ineffective in improving
visual acuity in the Central Vein Occlusion Study (CVOS)
[21,22]. Attempts to bypass venous obstruction in CRVO
using laser chorioretinal anastomosis have been per-
formed with limited success and significant complications
[3,11]. Radial optic neurotomy has been shown to be ben-
eficial for the treatment of CRVO [13]. Most patients who
develop CRVO (50 – 70%) have associated hypertension,
cardiovascular disease, or diabetes mellitus [5]. The treat-
ment of these systemic conditions is not effective in the
management of the ocular complications. It has been pos-
tulated that vitreous traction may play a role in the patho-
genesis of cystoid macular edema [16,17]. Eyes with
CRVO may be predisposed to vitreous degeneration. It has
been suggested that if the vitreous remains attached to the
macula owing to a firm vitreomacular adhesion, the
resultant vitreous traction can cause inflammation with
retinal capillary dilation, leakage and subsequent edema
[16]. Pars plana vitrectomy is believed to eliminate this
mechanical traction and increase oxygenation to the ret-
ina and to reduce the risk of macular edema and neovas-
cularization. The purpose of this study was to perform an
assessment of the safety and efficacy of pars plana vitrec-
tomy combined with complete posterior hyaloid removal
in ischemic CRVO.
Case presentation
Non comparative, prospective, longitudinal, experimen-
tal and descriptive series of cases of patients with ischemic
CRVO referred to Hospital Luis Sanchez Bulnes, Asoci-
ación para Evitar la Ceguera en México, México City. The
study was approved by Hospital Review Committee The
inclusion criteria were: confirmed presence of central reti-
nal vein occlusion, less than 6 months evolution with vis-
ual acuity (VA) of <20/100 or those whose VA decreased
more than 50% during the follow-up, an over 10 disc
diameter area of nonperfused retina, intraocular pressure
≤  21 mmHg, age ≥  21 years old, afferent pupillary defect,
ability to obtain good quality fundus photographs and
angiograms and absence of neovascularization. The exclu-
sion criteria in the study eye were: intercurrent eye disease
that is likely to affect VA over study period, presence of
any diabetic retinopathy, other retinal vascular disease,
vitreous hemorrhage, presence of neovascularization (iris,
angle, retina and disk) or previous laser treatment. Best
corrected ETDRS visual acuity (BCVA), relative afferent
pupillary defect (RAPD), slit-lamp examination, indirect
ophthalmoscopy, fundus photography, fluorescein angi-
ography (FA), multifocal electroretino*graphy (mERG)
and optic coherence tomography (OCT) were performed
preoperatively and at 1, 3, and 6 months postoperatively.
Follow-up was at least 6 months.
Surgical procedure
After informed consent was obtained and a full explana-
tion of the risks and benefits and the experimental nature
of this procedure were conveyed to the patient (in accord-
ance with the Helsinki declaration), patients underwent a
standard three port pars plana vitrectomy was performed,
during which the posterior hyaloid was removed using
active aspiration. The sclerostomy sites and conjunctiva
were closed in the usual fashion. No panretinal photoco-
agulation and gas tamponade were used.
OCT and mERG
Macular thickness was analyzed with OCT (Humphrey
1000; Humphrey Instruments, San Leandro, California).
Measurement of central macular thickness was evaluated
according to Hee protocol [7], which in each eye, six con-
secutive tomographic cuts were obtained in a radial pat-
tern, surrounding the fovea at similar angular distances
among them. Each one of these cuts was oriented along a
line that intersects the foveal center. The central foveal
thickness was registered at the intersection of the 6 cuts.
The electrical function of the macular area was deter-
mined by multifocal electroretinography (mERG). The
RETI-scan™ multifocal system, produced by Roland Con-
sult, was used for this purpose. The stimulation and
recording of the mERG were performed using the m-
sequence technique. Contact lens ERG-JET electrodes as
well as one ground electrode in the center of forehead and
two reference electrodes in the temporal region of the
patient were placed. The stimulus, consisting of 61 hexa-
gons covering a visual field of 30°, was presented on a
monitor (ELSA 20"-VGA-monitor) with a frame rate of 75
Hz at a distance of 28 cm from the patient's eye. Each ele-
ment alternated between black and white (93% contrast,
mean luminance 51.8 cd/m2). The patient was instructed
to maintain fixation on longitudinal axes intersecting one
focal point. The amplifier setting was 100 µV; the lower
cut off frequency was 10 Hz and the upper cut off fre-
quency was 100 Hz. No notch filter was used. Each record-
ing session was subdivided into 8 recording segments of
approximately 47 seconds. The signals were registered
with sampling intervals of 83 mseg. The results were dis-
tributed in 5 concentric rings obtaining for each ring, the
N1 amplitude, P1 amplitude, and the implicit times of N1
and P1. The amplitude of the positive component P1 wasBMC Ophthalmology 2005, 5:10 http://www.biomedcentral.com/1471-2415/5/10
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measured, and the response density (nV/deg2) was calcu-
lated by dividing the response amplitude (nV) by the ret-
inal area (deg2).
Results
The study data are displayed in Table 1 and 2. Patient's age
ranged from 57 to 74 years, with a mean of 65.13 years.
There were 4 females and 6 males. All patients were His-
panic. Initial treatment was attempted between January
2002 and February 2003. The time interval range from
diagnosis to treatment was 37 to 270 days, with a mean of
103.13 days. In all patients, the post treatment follow-up
examination was at least 6 months. Four patients had dia-
betes mellitus type 2 and six patients had systemic arterial
hypertension.
The median preoperative BCVA was 20/600 (range, 20/
1600 to 20/300). The median postoperative BCVA was
20/300 (range, 20/1600 to 20/100). VA was unchanged in
4 of 10 eyes (40%) and improved in 6 of 10 eyes (60%).
None eye had no light perception. The median preopera-
tive PIO was 15.7 ± 3.05 mmHg and the median postop-
erative PIO was 14.9 ± 2.68 mmHg. Central macular
edema registered by OCT changed from 976 ± 196 µm to
640 ± 191 µm to six month. The P1 wave amplitude of the
central ring varied from 25.46 ± 12.4 mV to 20.54 ± 11.2
mV to final follow up.
None eye suffered retinal o disc neovascular membrane.
The iris neovascularization was presented in 3 eyes (30%).
All these eyes were treated with extensive
photocoagulation. None of these eyes suffered neovascu-
lar glaucoma. Eight eyes presented middle opacity of lens.
Discussion
Fine and Brucker [4] and Wallow and 3 colleagues [25]
demonstrated that cystoid macular edema began with
ischemia and intracytoplasmic swelling of Müller cells,
and speculated that an intrinsic metabolic agent could
cause these changes. The vitreous is believed to store phar-
Table 1: Patients Characteristics
Case Age (years) Sex HBP DM Duration (days)* VA initial VA 3 month VA final Follow-Up (month)
1 57 M N N 120 20/1600 20/1600 20/1600 12
2 66 F N Y 66 20/1600 20/1600 20/800 10
3 72 M N Y 75 20/1600 20/1600 20/1600 8
4 70 M Y N 80 20/1600 20/1600 20/1600 8
5 59 M N Y 37 20/300 20/100 20/100 7
6 74 F Y Y 98 20/800 20/100 20/100 7
7 65 M Y N 65 20/300 20/300 20/200 6
8 58 M N N 80 20/1600 20/800 20/600 6
9 64 F Y N 180 20/1600 20/1600 20/1600 6
10 60 F Y N 90 20/600 20/300 20/300 6
HBP: high blood pressure; DM: diabetes mellitus; VA: visual acuity; IOP: intraocular pressure; M: masculine; F: feminine; Y: yes; N: no
* Time interval range from diagnosis to treatment
Table 2: IOP, macular thickness and mERG values
IOP mmHg Macular thickness (µm) OCT P1 wave amplitude (mV) mERG
Case Preop Postop Preop Postop Preop Postop
1 12 14 1100 800 44.2 16.4
2 16 18 1176 800 13.8 12.3
3 12 11 1200 750 7.0 30.2
4 18 16 1000 375 23.0 6.1
5 14 18 920 477 38.0 40.0
6 12 10 780 320 9.0 24.9
7 15 16 1000 700 23.8 14.7
8 20 18 1300 750 17.7 6.01
9 18 14 730 650 36.7 29.2
10 18 16 850 700 25.0 30.5
IOP: intraocular pressure; OCT: optic coherence tomography; mERG: multifocal electroretinogram; Preop: preoperative; Postop: postoperativeBMC Ophthalmology 2005, 5:10 http://www.biomedcentral.com/1471-2415/5/10
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macologic agents that may cause macular edema. Hikichi
and 2 colleagues[8] proposed that in eyes with vitreous
macular attachment, the macular edema is persistent
because those metabolic agents remain in contact with the
macula. Also they observed that a complete posterior vit-
reous detachment seems to protect against retinal or optic
disc neovascularization. Another theory asserts that
because vitreous fibres extending from the vitreous base to
the macula and Müller cell attachment to the internal lim-
iting lamina are prominent in this region [17,20] centrip-
etal traction caused by vitreous contraction after CRVO
and transmitted to Müller cells by the vitreous fibres
attached to the macula may cause swelling of these cells.
Kado and 6 colleagues [9] showed that macular edema
lasted longer in eyes with vitreous macular attachment
than in those whose vitreous was detachment from the
macula, due to centripetal traction transmitted to the
Müller cells by vitreous fibres inserted into the macula.
Based on these facts, we proposed that a vitrectomy could
eliminate the metabolic agents present in the vitreous as
well as the mechanical traction, and in this way might
protect against retinal and optic disc neovascularization.
Also, pars plana vitrectomy may beneficial effects upon
retinal ischemic by allowing circulation in the vitreous
cavity of fluid oxygenated by unaffected retina or others
sites in the eye such as the ciliary body [10,19]. In our
patients, a standard three port pars plana vitrectomy was
performed followed by creation of posterior hyaloid sep-
aration and removal of the posterior cortical vitreous. The
central macular edema registered by OCT changed from
976 ± 196 µm pre operative to 640 ± 191 µm to six
month. All patients presented persistent cystoid macular
edema to six month.
The level of visual improvement seems relatively good
when compared with the results of conventional treat-
ment such as retinal photocoagulation, or only observa-
tion. Although 40% of eyes maintained stable visual
acuity and 60% of eyes had visual improvement, there
was still considerable long-term visual morbidity in this
series. Only two eyes had final VA better than 20/200 (20/
100 in both eyes). The rest of eyes had a final VA of 20/
200 or less. Long-term visual morbidity may be corre-
sponding to residual perfused cystoid macular edema or
to degenerative squealer of previous chronic edema. None
patient presented significant complication post treatment
such as neovascular glaucoma or retinal detachment.
Most patients with CRVO lose their visual acuity perma-
nently because they develop macular edema or ischemia.
The degree of retinal hypoxia and infarction and probably
the extent of abnormal vascular permeability may be are
reflected in electroretinogram (ERG) amplitude and tim-
ing changes. In our patients, the P1 wave amplitude
changed from 25.46 ± 12.4 mV pre operative to 20.54 ±
11.2 mV to six month. Once the VA of these patients is
severely reduced, 80% of them cannot expect any
improvement spontaneously [2,14,23]. In this study, the
pre treatment visual acuity in all eyes ranged from 20/800
to 20/300 (20/300). It is recognized that earlier interven-
tion probably is favourable to later to prevent macular
scarring from longstanding edema [12,18]. In our series,
in eyes with early treatment (≤ 90 days), 4 eyes (67%)
improved VA and 2 eyes (33%) were unchanged. In eyes
with later treatment (>90 days), 2 eyes (50%) improved
VA and 2 eyes (50%) were unchanged.
In severe cases of ischemic CRVO, the role of the vitreous
was not observed. Increased venous pressure, which leads
to damage of the capillary endothelium and breakdown
of the blood-retinal barrier, was reported to be the main
cause of macular edema in CRVO [6,25]. Because capillary
damage may be aggravated sufficiently to negate the effect
of complete posterior vitreous detachment on macular
edema resolution in severe cases, the vitreoretinal rela-
tionship can only influence the prognosis of macular con-
ditions when there is mild capillary damage in the
macular region.
In the ischemic type of CRVO, the reported prevalence of
posterior segment and iris neovascularization ranges from
0% to 55% and from 16% to 67%, respectively
[15,20,23,24]. In our series, none eyes presented retinal or
optic neovascularization membrane. The iris neovascular-
ization was presented in 3 patients (30%). The posterior
vitreous detachment seems to play a protective role
against retinal or optic disc neovascularization in central
retinal vein occlusion [1,8], although the vitreoretinal
relationship may not influence the development of iris
neovascularization.
The efficacy and safety of vitrectomy in these patients is
still in question. Further studies such as a randomized
controlled clinical trial are needed to determine whether
vitrectomy is of benefit in ischaemic CRVO. Our results
suggest that a solo PPV with posterior hyaloid removal
may help to improve anatomic and functional retina con-
ditions in some cases. These results should be considered
when analyzing other surgical maneuvers.
Conclusion
A solo PPV with posterior hyaloid removal may help to
improve anatomic and functional retina conditions in
some cases. These results should be considered when ana-
lyzing other surgical maneuvers.
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